
    
      This is an interventional, randomized controlled, double-blind study (i.e., active and
      passive control), 1 intervention group will be randomized with COVID 19-001-USR, and a
      control group to receive a placebo intervention to assess efficacy, tolerance, and decrease
      viral load and clinical manifestation on patients infected with SARS-COV-2. This will be a
      self-administered study drug 3 times a day for 7 days
    
  